article thumbnail

3 Count: Notorious Markets 2025

Plagiarism Today

US releases 2025 Notorious Markets report, EFF files brief in DMCA subpoena case and House of the Dragon tops piracy lists. The post 3 Count: Notorious Markets 2025 appeared first on Plagiarism Today.

Marketing 264
article thumbnail

EMA Accepts Marketing Authorization Application for Alvotech’s AVT06 (aflibercept)

JD Supra Law

On August 15, 2024, Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s biosimilar of low dose (2 mg) EYLEA (aflibercept). By: Goodwin

Marketing 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SAVE THE DATE: Internet Law Works-in-Progress Conference, SCU, March 8, 2025

Technology & Marketing Law Blog

The conference will be hosted by the High Tech Law Institute and held at Santa Clara University School of Law on March 8, 2025. The post SAVE THE DATE: Internet Law Works-in-Progress Conference, SCU, March 8, 2025 appeared first on Technology & Marketing Law Blog. We can’t wait to see you in person!

Law 111
article thumbnail

5 Litigation Funding Trends To Note In 2025

IP Law 360

Lawyers and their clients must be prepared to navigate an evolving litigation funding market in 2025, made more complicated by a new administration and the increasing overall cost of litigation, says Jeffery Lula at GLS Capital.

article thumbnail

Small-Market Segment Can Satisfy Domestic Industry Requirement

JD Supra Law

The US Court of Appeals for the Federal Circuit affirmed a US International Trade Commission finding, explaining that small-market segments can be significant and substantial enough to support the Commissions domestic industry requirement. 7, 2025) (Moore, Chen, Murphy, JJ.). Wuhan Healthgen Biotechnology Corp. 23-1389, (Fed.

article thumbnail

Patent Case Summaries | Week Ending January 10, 2025

JD Supra Law

The FDA approved a New Drug Application from Novartis for a combination therapy of valsartan and sacubitril, which Novartis markets and sells under the brand name Entresto. Torrent Pharma Inc., 2023-2218, -2220, -2221 (Fed. Opinion by Lourie, joined by Prost and Reyna.

article thumbnail

Use of AI in Marketing and Digital Media - 2025 Playbook

JD Supra Law

Right now, we are all taking stock of the many important issues and challenges we saw crop up for clients last year, trying to predict what they will face in the coming year, and strategizing about how we can help. By: BakerHostetler